Mr. Speaker, yesterday, before the Standing Committee on Health and here in the House, the Minister of Health insisted that all of the relevant information regarding the Cipro affair was included in his department's affidavit and that it answered all our questions.
We have now learned that a second generic drug company, Novopharm, was approached on October 15 to meet the demand for Cipro.
If the affidavit was indeed complete, why then did it make no mention of Novopharm?